BOPA Questionnaire – Monitoring and Treatments for Immune-Related Myocarditis

The BOPA Immunotherapy Specialist Interest Group invites all BOPA members to complete this survey.
This builds on our previous work exploring the known disparity across the UK with regards to access to drugs for immune-related (IR) adverse effects. IR-myocarditis is a rare and serious complication of immune checkpoint inhibitors (ICI).

Firstly, we aim to understand what cardiac assessments are undertaken prior to ICI therapy and the monitoring during therapy. Also we are wanting to discover which drugs and in particular which steroid sparing agents are prescribed for IR-myocarditis. Please find below the link and a QR code to take you to the survey, which should take around 12 minutes to complete. Analysis of these results will be used to highlight the difficulties in treating patients with this life-threatening IR adverse effect.

https://forms.office.com/e/bURF4jkFNN

Please get in touch if you have any queries and thank you for your contribution.

Simon, Meera, Jo, Dharmisha and Alice

The BOPA Immunotherapy Specialist Interest Group

And the Research Subcommittee

Latest News

By BOPA on 31st August 2026

🌟 BOPA Advanced Pharmacist Study Day – Elevate Your Practice, Shape Your Career

Are you an oncology or haematology pharmacist with around five or more years of experience — whether Band 7 or Band 8 — and ready to take the next step…

Read article
By BOPA Executive Committee on 31st August 2026

BOPA 2026 Executive Committee Election – One week left to cast your vote

One week left to cast your vote for the BOPA Executive Committee Election. Have your say at BOPA’s future.   In 2026 we received 9 nominations for 6 positions. -Standard…

Read article
By BOPA Executive Committee on 27th August 2026

UK multidisciplinary Consensus Document – Safe Management of Hazardous Medicinal Products in UK Healthcare Settings

We are pleased to jointly publish the new UK multidisciplinary consensus document, Safe Management of Hazardous Medicinal Products in UK Healthcare Settings. Hazardous medicinal products (HMPs) are used across a…

Read article
By BOPA Executive Committee on 24th August 2026

BOPA 2026 Executive Committee Election – Have you cast your vote for your candidates?

Have you cast your vote for the 2026 BOPA Executive Committee Election? In 2026 we received 9 nominations for 6 positions. -Standard Committee Member (6 places available) – VOTING FOR…

Read article